Long-acting beta(2)-agonists

The LABAs salmeterol and formoterol have both prolonged airway smooth muscl e effects and non-bronchodilator activity. They have a complementary mode o f action to the topical anti-inflammatory effects of corticosteroids, and i nhibit mucosal oedema, increase mucociliary transport and reduce respirator y tract infection. In asthma, LABAs are currently positioned as 'add-on' th erapy, where combination with inhaled steroids results in better lung funct ion and symptom control, decreased rescue medication and fewer exacerbation s. In COPD patients, LABAs such as salmeterol reduce breathlessness, decrea se exacerbations and improve health-related quality of life.